ABBVIE INC (ABBV)
US00287Y1091 - Common Stock
ABBVIE INC
NYSE:ABBV (4/26/2024, 9:49:06 AM)
161.6
-5.69 (-3.4%)
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. The company offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, and more. The Company, through Mitokinin, Inc., offers a lead compound, PINK1 activator, designed to address mitochondrial dysfunction.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS 60064
P: 18479327900
CEO: Richard A. Gonzalez
Employees: 50000
Website: https://www.abbvie.com/
ABBV News
2 hours ago - Investor's Business DailyAbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's TitleSkyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira.
3 hours ago - BloombergAbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira LossesAbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq and Skyrizi take over for Humira, the blockbuster arthritis drug that fueled the company’s growth for more than 15 years.
3 hours ago - AbbVieAbbVie Reports First-Quarter 2024 Financial ResultsReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...
20 hours ago - Market News VideoNoteworthy Thursday Option Activity: INTC, ABBV, BYON
a day ago - InvestorPlace3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionMany fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
3 days ago - InvestorPlaceDividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate HikesIt's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay.
ABBV Twits
Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
